113 related articles for article (PubMed ID: 18562256)
1. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
[TBL] [Abstract][Full Text] [Related]
2. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Guichard SM; Macpherson JS; Mayer I; Reid E; Muir M; Dodds M; Alexander S; Jodrell DI
Eur J Cancer; 2008 Jan; 44(2):310-7. PubMed ID: 18077151
[TBL] [Abstract][Full Text] [Related]
3. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Parise RA; Egorin MJ; Eiseman JL; Joseph E; Covey JM; Beumer JH
Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications.
Shindoh H; Nakano K; Yoshida T; Ishigai M
J Toxicol Sci; 2011 Aug; 36(4):411-22. PubMed ID: 21804305
[TBL] [Abstract][Full Text] [Related]
5. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
[TBL] [Abstract][Full Text] [Related]
6. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
Xiang TX; Niemi R; Bummer P; Anderson BD
J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
[TBL] [Abstract][Full Text] [Related]
7. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
Chung YL; Troy H; Judson IR; Leek R; Leach MO; Stubbs M; Harris AL; Griffiths JR
Clin Cancer Res; 2004 Jun; 10(11):3863-70. PubMed ID: 15173095
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
[TBL] [Abstract][Full Text] [Related]
10. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
12. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
13. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
14. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
Mercier C; Dupuis C; Blesius A; Fanciullino R; Yang CG; Padovani L; Giacometti S; Frances N; Iliadis A; Duffaud F; Ciccolini J
Cancer Chemother Pharmacol; 2009 May; 63(6):1177-80. PubMed ID: 19107485
[TBL] [Abstract][Full Text] [Related]
15. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
[TBL] [Abstract][Full Text] [Related]
16. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
[TBL] [Abstract][Full Text] [Related]
17. Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver.
Klomp D; van Laarhoven H; Scheenen T; Kamm Y; Heerschap A
NMR Biomed; 2007 Aug; 20(5):485-92. PubMed ID: 17131325
[TBL] [Abstract][Full Text] [Related]
18. Diurnal Changes in Capecitabine Clock-Controlled Metabolism Enzymes Are Responsible for Its Pharmacokinetics in Male Mice.
Akyel YK; Ozturk Civelek D; Ozturk Seyhan N; Gul S; Gazioglu I; Pala Kara Z; Lévi F; Kavakli IH; Okyar A
J Biol Rhythms; 2023 Apr; 38(2):171-184. PubMed ID: 36762608
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Ferraris D; Duvall B; Delahanty G; Mistry B; Alt J; Rojas C; Rowbottom C; Sanders K; Schuck E; Huang KC; Redkar S; Slusher BB; Tsukamoto T
J Med Chem; 2014 Mar; 57(6):2582-8. PubMed ID: 24520856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
